Sanitas AB - Notification on material event

NOTIFICATION OF THE PROPOSED TRANSACTION TO COMPETITION AUTHORITIRES

Kaunas, Lithuania, 2011-06-08 18:34 CEST (GLOBE NEWSWIRE) -- AB Sanitas
announces that Valeant Pharmaceuticals International, Inc. (“Valeant”) today,
Wednesday 8th June 2011, has submitted applications to the Competition Council
of the Republic of Lithuania and the Polish Office for Competition and Consumer
Protection for clearance of the proposed transaction. As announced on 24th May
2011, the funds advised by Citi Venture Capital International (“CVCI”, through
the legal entities Citigroup Venture Capital International Jersey Limited and
Baltic Pharma Limited), AB Invalda (“Invalda”), Amber Trust II S.C.A. (“Amber”)
and certain other persons (together the “Controlling Shareholders”), on 23rd
May 2011, entered into a definitive share sale and purchase agreement for the
sale of their entire 87.2% shareholding in AB Sanitas to Valeant. More
information is available at:
http://www.sanitasgroup.com/index.php/news/news/the-signature-date-of-the-share-
sale-and-purchase-agreement-has-been-corrected/11468. 
A further announcement will be made when appropriate.
This announcement is also available on AB Sanitas' website:
www.sanitasgroup.com. 

A person authorised to provide additional information: Mr. Saulius Jurgelėnas,
Chief Executive Officer of AB Sanitas, phone number +370 686 67779. 


         Lawyer
         Dovilė Morkytė
         +370 37 200662